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able prospective cohort of patients on mifepristone, and the 
scarcity of data on its long-term effects, does not allow rec-
ommending it as a first-line drug in the treatment of hyper-
cortisolism. However, as mifepristone is a rapidly effective 
drug, it can play a role in the management of hypercorti-
solism. The main indication is the partial efficacy or bad tol-
erance of other well-known anticortisolic drugs, either by re-
placement (bad tolerance, lack of effectiveness) or addition 
(multimodal approach) of mifepristone. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Cushing’s syndrome can be caused by adrenal, pitu-
itary or ectopic tumors. Surgery remains the first-line 
treatment, and can be followed by pituitary irradiation or 
bilateral adrenalectomy if necessary. Medical manage-
ment remains, however, of major interest when surgery is 
impossible, in preparation for surgery, or when surgery is 
partially effective. The efficacy of usual anticortisolic 
drugs (ketoconazole, metyrapone, mitotane, etc.) is not 
constant and may be limited by their poor tolerance  [1, 2] . 
Mifepristone, a glucocorticoid receptor antagonist ini-
tially considered as a so-called ‘contragestive’ pill, may 
represent an alternative  [3] . Our recent European collab-
orative retrospective study  [3] allowed to discuss the po-
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 Abstract 
 Mifepristone is the first and only available glucocorticoid re-
ceptor antagonist. It was initially mainly considered as a so-
called ‘contragestive’ pill due to its antiprogestin activity. In 
this review, we summarize the results of mifepristone report-
ed in the literature as a treatment of Cushing’s syndrome. 
Most of the patients were treated due to unsuccessful sur-
gery and/or partially effective anticortisolic drugs. The ma-
jority of them presented a rapid decrease of clinical signs of 
hypercortisolism during the first month of treatment; about 
half experienced a reduction in their elevated blood pres-
sure, and half of the diabetic patients presented improved 
blood glucose levels. Mifepristone treatment has 2 main 
drawbacks: (1) the blockade of glucocorticoid receptors 
leads to increased ACTH and cortisol levels, making it diffi-
cult to adapt the treatment and diagnose adrenal deficien-
cy, and (2) increased cortisol levels can also lead to severe 
hy pokalemia. Follow-up of efficacy should only be clinical 
(weight, blood pressure, skin lesions) and biological (regular 
blood potassium sampling). Dose adjustment will be per-
formed based on these parameters. The lack of a large avail-
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tential future role of this drug in the management of 
Cushing’s syndrome. In the present review, we will main-
ly talk about mifepristone, as data about other potential 
glucocorticoid receptor antagonists are only experimen-
tal.
 Pharmaceutical Properties 
 Mifepristone is a substituted 19-nor steroid compound
chemically designated as 11  -[ p -(dimethylamino)phe-
nyl]-17  -hydroxy-17-(1-propynyl)estra-4,9-dien-3-one. 
It is the first and currently only available glucocorticoid 
receptor antagonist treatment  [4] . Other glucocorticoid 
receptors are currently evaluated, but no clinical trial 
has been published to date  [5] . Mifepristone has also a 
strong anti-progestin activity, and a weak anti-androgen 
activity: its relative binding affinity at the glucocorti-
coid receptor is more than three times that of dexameth-
asone and more than ten times that of cortisol; affinity 
at the progesterone receptor is more than twice that of 
progesterone, and affinity at the androgen receptor is 
less than one third that of testosterone. It does not bind 
to the estrogen receptor or the mineralocorticoid recep-
tor. Following oral administration of a single dose of 
400–600 mg, mifepristone is rapidly absorbed, with a 
peak plasma concentration occurring approximately 90 
min after ingestion. Of note, in the absence of progester-
one or cortisol, mifepristone can also act as a weak ago-
nist  [5, 6] . 
 Efficacy 
 Mifepristone appears as a rapidly effective drug in 
controlling signs of hypercortisolism. To date, 37 pa-
tients, mainly adults, have been reported in the literature 
as having received mifepristone for various etiologies of 
Cushing’s syndrome ( table 1 )  [7–16] . Most of them were 
treated due to unsuccessful surgery and partially effec-
tive or badly tolerated medical treatment. Up to 85% pre-
sented a decrease of their clinical signs of hypercorti-
solism (weight loss, improvement of skin signs) during 
the first month of mifepristone ( fig. 1 ). About half expe-
rienced a reduction in their elevated blood pressure and 
half of the diabetic patients also presented improved 
blood glucose levels, sometimes leading to withdrawal
of antidiabetic drugs. The majority of the patients have 
been treated for an advanced adrenal carcinoma, ectopic 
ACTH secretion or Cushing’s disease. 
 Adrenal Carcinoma 
 Seventeen patients have been reported to date. In the 
majority of cases, mifepristone was given in advanced ad-
renal carcinomas after failed surgery, and lack of efficacy 
of classical anticortisolic drugs (including mitotane). Me-
dian duration of treatment was 3 months (range 0.25–9). 
Clinical signs of hypercortisolism improved in 76% of
the cases during the first month of treatment. In our se-
ries, 60% of the patients presented improved blood pres-
sure levels. Interestingly, one patient with severe psycho-
sis had a drastic improvement of psychiatric signs in the 
first few days of mifepristone treatment.
 Ectopic ACTH Secretion 
 Twelve patients have been treated with mifepristone 
after unsuccessful surgery or lack of identified tumor. 
Median duration of treatment was 5.5 months (range 
0.3–18). All patients presented an improvement of their 
clinical signs. About half of them experienced decreased 
blood pressure levels. Severe psychosis signs improved 
in the first few days of mifepristone treatment in 1 pa-
tient.
 Fig. 1. Clinical picture of a patient before 
(left) and 6 months after (right) treatment 
with mifepristone for an ectopic ACTH 
syndrome. Note the decrease in upper 
body obesity and facial erythrosis after 
treatment. 
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 Cushing’s Disease 
 Five patients have been treated to date because of the 
lack of pituitary adenoma visualized on MRI, failed sur-
gery, bad tolerance to other anticortisolic drugs or partial 
efficacy of a radiosurgical procedure. Mean duration of 
treatment was 11 months (range 0.5–24). All but one pa-
tient presented improved clinical signs. Again, 1 patient 
with severe psychosis had a drastic improvement of psy-
chiatric signs in the first few days of mifepristone treat-
ment.
Table 1.  Individual data of patients treated with mifepristone for adrenal carcinoma (patients 1–17), ectopic ACTH secretion (18–29), 
Cushing’s disease (30–34) or other causes (35–37)
Patient 
No.
Sex/
age
Dose
mg/day
Previous 
treatments
Duration
months
High 
BP
Hypoka-
lemia
Adrenal 
insufficiency
Diabetes
1 F/45 5–22 mg/kg 2
2 F/32 400 2
3 F/NA 20–30 mg/kg 4
4 M/62 400 9 d
5 M/43 400–800 mg 0.5
6 M/63 1,000 M 6 f } f
7 F/39 400 M 2.5 } d –
8 F/52 400–600 M 3 f d –
9 F/52 400–600 M 3 f d }
10 F/45 400–2,000 M+K 1 – d –
11 F/63 600 M+K 2 } – d –
12 M/20 600–1,200 M+K 1 f d d }
13 F/47 400–1,200 M+K 2 } d –
14 F/38 400–600 M+m 3 – – –
15 F/44 200–600 M+m 2 – – –
16 M/64 200–400 M+m 1.5 – – –
17 M/52 600 M+E 0.25 – d }
18 M/36 5–22 mg/kg 10 d
19 M/42 5–22 mg/kg 12
20 F/63 5–22 mg/kg 4 d
21 F/55 5–22 mg/kg 2.5
22 F/46 800–1,600 0.3
23 M/25 5–20 mg/kg m+chemotherapy 2.5 f f f
24 F/2 75–300 none 2 f – f
25 F/46 600 chemotherapy 2 d d f
26 F/37 800 chemotherapy 10 d d –
27 M/55 400–600 E+m 1 f d f
28 F/43 600 K 2 d d f
29 F/38 400–800 K 18 d d –
30 M/45 400–800 K 12 – – –
31 M/56 600–1,200 K 24 – – d –
32 F/50 600 – 0.5 – } –
33 F/45 600 – 3 d d –
34 M/51 400–2,000 K 18 } d d –
35 F/38 5–22 mg/kg – 1.5
36 F/52 600 K 6 – } f
37 F/14 400 – 8 – – –
Previous treatments are treatments administered before the start of mifepristone therapy: M = mitotane; K = ketoconazole; m = 
metyrapone; E = etomidate. High blood pressure (BP), hypokalemia, adrenal insufficiency and diabetes: f = alleviation or improve-
ment on mifepristone; d = worsening or onset on mifepristone; } = unchanged on mifepristone; – = absent before treatment, unchanged 
on mifepristone; blank space for patients 1–5 = not available.
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 Of note, 1 patient has been treated for bilateral adrenal 
hyperplasia, and 2 for a likely benign adrenal adenoma 
(but the precise etiology is unclear). All of them experi-
enced a rapid improvement of clinical signs of hyper-
cortisolism during the first month of mifepristone treat-
ment  [10] .
 Tolerance 
 In Cushing’s syndrome, hypokalemia is directly relat-
ed to glucocorticoid excess as massive hypercortisole-
mia leads to incomplete renal inactivation of cortisol by 
11  -dehydrogenase, and hence mineralocorticoid excess. 
Mifepristone requires careful medical attention and a 
close follow-up of this specific point. As mifepristone 
blocks only glucocorticoid action, the mineralocorticoid 
activity of cortisol excess is not affected by mifepristone 
treatment, thus leading to hypokalemia. On the contrary, 
mifepristone may lead to an increase of plasma ACTH 
and consecutively of cortisol levels in some patients with 
Cushing’s syndrome, particularly with Cushing’s disease 
due to alterations in negative feedback (a mechanism of 
hypokalemia similar to the one observed in Cushing’s 
syndrome without treatment)  [5] . Mifepristone-induced 
hypokalemia was observed in one third of the 37 Cush-
ing’s patients reported to date. In a few cases, hypokale-
mia was very severe, requiring high doses of oral and
intravenous potassium, and intensive anti-aldosterone 
treatment. Severe hypokalemia should thus represent a 
contraindication for this treatment and potassium levels 
need to be carefully monitored. The same mechanism 
can induce increased blood pressure levels, which was ob-
served in 5 patients, despite an improvement of clinical 
signs of hypercortisolism. The ideal treatment remains 
high dose anti-aldosterone treatment: there is no need
for a systematic prescription at the onset of mifepristone, 
except in case of low-normal hypokalemia.
 Moreover, the lack of available biological parameters 
of follow-up on treatment obviously represents a limita-
tion for the use of mifepristone. Signs suggestive of adre-
nal insufficiency have been reported in 16% of the 37 pa-
tients reported to date. The blockade of glucocorticoid 
receptors does not allow determining the efficacy of the 
drug by measuring ACTH and cortisol levels that are in-
creased by mifepristone treatment. However, this low rate 
of adrenal deficiency is puzzling taking into account the 
mechanism of action of mifepristone: it is probably due 
to a partial blockade of glucocorticoid receptor antago-
nists, or a weak agonist effect of the drug  [5] . Manage-
ment of adrenal deficiency is also difficult: hydrocorti-
sone is not effective; dexamethasone (1 mg for 400 mg of 
mifepristone) should be given during 48 h in parallel with 
mifepristone withdrawal. Mifepristone can be re-initiat-
ed at a lower dose after the treatment of adrenal deficien-
cy  [17] .
 Antiprogestin effects are also important to notice as 
they can induce an endometrial hyperplasia (relative hy-
perestrogenia). Three patients have been reported in the 
literature with this adverse effect  [14] . Pelvic ultrasonog-
raphy should be performed yearly in every woman before 
menopause.
 Dose and Follow-Up 
 Mifepristone should be initiated at a low dose (200–
400 mg/day), and increased every 2–4 weeks based on 
clinical efficacy and tolerance. The maximal dose given 
should be around 400–800 mg/day. Increasing the dose 
up to 1,000 mg/day is usually not necessary, and increas-
es the risk of adverse effects. However, increase in the 
dose of mifepristone could be performed more rapidly in 
case of severe signs of psychosis  [10] .
 Follow-up of efficacy, and dose adjustments should 
mainly rely on clinical and necessarily imperfect param-
eters like weight, blood pressure or skin lesions. ACTH 
and cortisol levels will be increased, and do not represent 
a good marker of the efficacy of the drug. Adrenal defi-
ciency should be suspected in case of weakness, fatigue, 
nausea, vomiting, and hypoglycemic episodes  [10] .
 As mentioned previously, only a limited number of pa-
tients have been treated long-term with mifepristone, 
probably because more than a third of patients reported 
to date presented an advanced adrenal carcinoma. If 
long-term treatment is considered, pelvic ultrasonogra-
phy should be performed at least yearly in nonmenopaus-
al women. No specific adverse effects other than the ones 
seen at short-term have been reported.
 Pros and Cons in Comparison with Other 
Anticortisolic Drugs 
 The potential risks and benefits of mifepristone have 
to be weighed against alternative treatment options. The 
majority of other anticortisolic drugs have the major ad-
vantage to induce decreased cortisol levels: they are thus 
easier to follow (regular measures of plasma cortisol lev-
els), whereas during mifepristone, cortisol concentration 
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provides no guidance for treatment. However, the other 
anticortisolic drugs classically expose patients to fre-
quent and/or severe side effects without superior efficacy. 
Ketoconazole has been reported to induce serious and 
life-threatening hepatotoxicity, although this side effect 
is rare (1/15,000 cases). Moreover, ketoconazole is no lon-
ger available in some European countries (e.g. Germany) 
 [2] . Metyrapone, an inhibitor of 11  -hydroxylase, is not 
easily available in several European countries and may 
also be associated with significant side effects  [18] . Etomi-
date can only be used intravenously and, therefore, should 
be reserved for severe cases  [19] . The use of mitotane can 
be difficult due to a narrow therapeutic window, and 
overall bad tolerance (gastrointestinal and neurotoxic ef-
fects). Moreover, most of these treatments are not as rap-
idly effective as mifepristone. This is particularly true for 
mitotane, which requires several weeks before being ful-
ly effective  [20, 21] .
 Thus, treatment with mifepristone may be of signifi-
cant value in the medical treatment of Cushing’s syn-
drome in a high percentage of cases. Its place must be 
defined in regards of the severity of the disease. Due to 
the low number of patients reported, mifepristone cannot 
be recommended as a first-line treatment, even in com-
parison with more classical anticortisolic drugs. Mife-
pristone should be reserved to patients with lack of/par-
tial efficacy and/or bad tolerance of well-known thera-
peutic procedures, i.e. surgery, radiotherapy and other 
anticortisolic drugs. Of note, mifepristone can be added 
to other anticortisolic drugs, as they have different mech-
anisms of actions. In this case, follow-up (mainly in terms 
of signs of adrenal deficiency and potassium levels) 
should be very strict.
 Conclusion 
 Mifepristone represents a rapidly effective treatment 
to control signs of hypercortisolism with the main draw-
back of the impossibility to follow blood cortisol levels. 
The risk of severe hypokalemia needs to be closely moni-
tored and further limits its widespread use. Despite these 
promising results, the lack of a large available prospective 
cohort of patients on mifepristone, and the scarcity of 
data on its long-term effects, does not allow recommend-
ing it as a first-line drug in the treatment of hypercorti-
solism. However, as mifepristone is a rapidly effective 
drug, its main indication is the partial efficacy or bad tol-
erance of other well-known anticortisolic drugs especial-
ly in patients with psychiatric signs of hypercortisolism. 
Only a limited number of patients have been treated long-
term with mifepristone and if long-term treatment is con-
sidered, one should keep in mind the anti-progestin ac-
tivity of mifepristone, as this can lead to endometrial hy-
perplasia.
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